Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Drug: Anastrazole 1mgRadiation: Adjuvant chemotherapy
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 140
- Registration Number
- NCT06953882
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
RGD With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect
- Conditions
- Intrabony DefectPeriodontal DiseasesAlveolar Bone Loss
- Interventions
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Minia University
- Target Recruit Count
- 45
- Registration Number
- NCT06936605
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751966
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751901
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752044
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional second-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751914
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock
- Conditions
- Sepsis-induced Cardiomyopathy
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06745206
BZLF1 Peptide Vaccine (OSU-2131) with QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
- Conditions
- Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative DisorderEBV-Related Malignant NeoplasmPost-Transplant Lymphoproliferative Disorder
- Interventions
- Procedure: Biospecimen CollectionDrug: Dulbecco''s Phosphate-Buffered Saline
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 55
- Registration Number
- NCT06741072
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06575257
- Locations
- 🇨🇳
The First Affillated Hospital, the Air Force Medical University, Xi'an, Shanxi, China
Effect of a GnRH Analog on Hepatic Steatosis
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver DiseaseNonalcoholic Fatty LiverEndometriosis
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 62
- Registration Number
- NCT06523530
- Locations
- 🇬🇷
424 General Military Hospital, Thessaloniki, Greece
🇬🇷1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloníki, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.